Search research articles
Contact Us
Filters
Showing results (71-80 of 80) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 80 results.
Neurobiology of Disease
|
February 27, 2022
Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism
Francisco Molinet-Dronda, Javier Blesa, Natalia López-González Del Rey, et al.
Oncology and Therapy
|
December 12, 2022
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
Adrián Alegre, Gonzalo Benzo, Rafael Alonso, et al.
Leukemia & Lymphoma
|
June 27, 2009
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
Joaquin Martínez-López, Ana Rivero, Inmaculada Rapado, et al.
Seminars in Hematology
|
December 4, 2018
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
Felipe de Arriba de la Fuente, Maria Soledad Durán, Miguel Ángel Álvarez, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 2, 2025
Development of PREVEMM: A Venous Thromboembolism Risk Score for Newly Diagnosed Multiple Myeloma Patients
Inés Martínez-Alfonzo, Diego Velasco-Rodríguez, Pablo Mínguez-Paniagua, et al.
Leukemia Research
|
December 14, 2011
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Blanca Sanchez-Gonzalez, F Javier Peñalver, Angeles Medina, et al.
Journal of Thrombosis and Thrombolysis
|
January 11, 2023
Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma
Diego Velasco-Rodríguez, Inés Martínez-Alfonzo, Alberto Eterio Velasco-Valdazo, et al.
Blood Cancer Journal
|
October 20, 2020
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, et al.
Journal of Thrombosis and Thrombolysis
|
March 11, 2025
Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy
Diego Velasco-Rodríguez, Inés Martínez-Alfonzo, Alberto Eterio Velasco-Valdazo, et al.
The Lancet. Haematology
|
August 6, 2025
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
María-Victoria Mateos, Bruno Paiva, M Teresa Cedena, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 80) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 80 results.
Neurobiology of Disease
|
February 27, 2022
Cerebral metabolic pattern associated with progressive parkinsonism in non-human primates reveals early cortical hypometabolism
Francisco Molinet-Dronda, Javier Blesa, Natalia López-González Del Rey, et al.
Oncology and Therapy
|
December 12, 2022
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP)
Adrián Alegre, Gonzalo Benzo, Rafael Alonso, et al.
Leukemia & Lymphoma
|
June 27, 2009
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide
Joaquin Martínez-López, Ana Rivero, Inmaculada Rapado, et al.
Seminars in Hematology
|
December 4, 2018
Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation
Felipe de Arriba de la Fuente, Maria Soledad Durán, Miguel Ángel Álvarez, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 2, 2025
Development of PREVEMM: A Venous Thromboembolism Risk Score for Newly Diagnosed Multiple Myeloma Patients
Inés Martínez-Alfonzo, Diego Velasco-Rodríguez, Pablo Mínguez-Paniagua, et al.
Leukemia Research
|
December 14, 2011
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
Blanca Sanchez-Gonzalez, F Javier Peñalver, Angeles Medina, et al.
Journal of Thrombosis and Thrombolysis
|
January 11, 2023
Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma
Diego Velasco-Rodríguez, Inés Martínez-Alfonzo, Alberto Eterio Velasco-Valdazo, et al.
Blood Cancer Journal
|
October 20, 2020
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, et al.
Journal of Thrombosis and Thrombolysis
|
March 11, 2025
Significant attenuation of fully automated thrombin generation in newly diagnosed multiple myeloma patients after induction therapy
Diego Velasco-Rodríguez, Inés Martínez-Alfonzo, Alberto Eterio Velasco-Valdazo, et al.
The Lancet. Haematology
|
August 6, 2025
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial
María-Victoria Mateos, Bruno Paiva, M Teresa Cedena, et al.
Page
of 8